Emerging pharmacologic therapies for constipation-predominant irritable bowel syndrome and chronic constipation

Journal of Neurogastroenterology and Motility

Volumn 20, Issue 2, 2014, Pages 141-151

  Eswaran, Shanti ^a   Guentner, Amanda ^a   Chey, William D ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Bile acid and salts; Constipation; Irritable bowel syndrome; Laxatives; Therapeutics

Indexed keywords

BISACODYL; CHENODEOXYCHOLIC ACID; DAIKENCHUTO; ELOBIXIBAT; HEMP SEED EXTRACT; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MOSAPRIDE; PICOSULFATE SODIUM; PLANT EXTRACT; PLECANATIDE; PROBIOTIC AGENT; PRUCALOPRIDE; PUMOSETRAG; RDX 5791; TU 100; UNCLASSIFIED DRUG;

ACTINIDIA DELICIOSA; CHINESE MEDICINE; CHRONIC DISEASE; CONSTIPATION; CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME; DIET SUPPLEMENTATION; GASTROENTEROLOGIST; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; IRRITABLE COLON; META ANALYSIS (TOPIC); NONHUMAN; PATHOGENESIS; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLUM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE;

EID: 84897552764     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2014.20.2.141     Document Type: Review

References (88)

1. Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97:1910-1915.
2. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004;99:750-759
3. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-721, e4.
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC.Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
5. Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010;139: 1549-1558, e1.
6. Simren M, Bajor A, Gillberg PG, Rudling M, Abrahamsson H. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study. Aliment Pharmacol Ther 2011;34:41-50.
7. Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 2011;106:2154-2164.
8. Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011;106:1803-1812.
9. Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci 2013;58:2580-2586.
10. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-365.
11. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-254.
12. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-328.
13. Nakamura M, Ohmiya N, Miyahara R, et al. Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 receptor agonist mosapride. Hepatogastroenterology 2011;58:453-458.
14. Fujita T, Yokota S, Sawada M, Majima M, Ohtani Y, Kumagai Y. Effect of MKC-733, a 5-HT3 receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. J Clin Pharm Ther 2005;30:611-622.
15. Manabe N, Camilleri M, Rao A, et al. Effect of daikenchuto (TU- 100) on gastrointestinal and colonic transit in humans. Am J Physiol Gastrointest Liver Physiol 2010;298:G970-G975.
16. Iturrino J, Camilleri M, Wong BS, Linker Nord SJ, Burton D, Zinsmeister AR. Randomised clinical trial: the effects of daikenchuto, TU-100, on gastrointestinal and colonic transit, anorectal and bowel function in female patients with functional constipation. Aliment Pharmacol Ther 2013;37:776-785.
17. Cheng CW, Bian ZX, Zhu LX, Wu JC, Sung JJ. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am J Gastroenterol 2011;106:120-129.
18. Wong RK, Palsson OS, Turner MJ, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol 2010;105:2228- 2234.
19. Shekhar C, Monaghan PJ, Morris J, et al. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology 2013;145:749-757.
20. Eswaran S, Muir J, Chey WD. Fiber and functional gastrointestinal disorders. Am J Gastroenterol 2013;108:718-727.
21. Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol 2010;105:897-903.
22. Kamm MA, Muller-Lissner S, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo- controlled multinational study. Am J Gastroenterol 2005;100: 362-372.
23. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-177.
24. Kamm MA, Müller-Lissner SA, Wald A, et al. S1321 stimulant laxatives are effective in chronic constipation: multi-center, 4-week, double- blind, randomized, placebo-controlled trial of bisacodyl. Gastroenterology 2010;138(suppl 1):S-228.
25. Dufour P, Gendre P. Ultrastructure of mouse intestinal mucosa and changes observed after long term anthraquinone administration. Gut 1984;25:1358-1363.
26. Kiernan JA, Heinicke EA. Sennosides do not kill myenteric neurons in the colon of the rat or mouse. Neuroscience 1989;30:837-842.
27. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005;100(suppl 1):S1-S4.
28. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011;60:209-218.
29. Dipalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol 2007;102:1436-1441.
30. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013;108:1508-1515.
31. Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:191-196.
32. Menees S, Saad R, Chey WD. Agents that act luminally to treat diarrhoea and constipation. Nat Rev Gastroenterol Hepatol 2012;9:661- 674.
33. Jun JY. Role of lubiprostone on gastrointestinal motility. J Neurogastroenterol Motil 2013;19:277-278.
34. Chan WW, Mashimo H. Lubiprostone increases small intestinal smooth muscle contractions through a prostaglandin E receptor 1 (EP1)-mediated pathway. J Neurogastroenterol Motil 2013;19:312- 318.
35. Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 2008;154:126-135.
36. Fukudo S, Hongo M, Kaneko H, Ueno R. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil 2011;23:544, e205.
37. Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010;55:1090-1097.
38. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-341.
39. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double- blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25:1351-1361.
40. Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012;35:587-599.
41. Cryer BL, Katz S, Vallejo R. A phase 3, randomized, double-blind, placebo-controlled clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction in patients with chronic, non-cancer pain. Gastroenterology 2010;138(suppl 1):S-129.
42. Mazen Jamal M, Mareya SM, Woldegeorgis F, Joswick RT, Joswick RU. Lubiprostone significantly improves treatment response in non-methadone opioid-induced bowel dysfunction patients with chronic, non-cancer pain: results from a phase 3, randomized, double- blind, placebo-controlled clinical trial. Gastroenterology 2012; 142(suppl 1):S144-S145.
43. Ueno R, Wahle A, Rivera E. Pooled analysis of the most frequent adverse events associated with the use of lubiprostone. Am J Gastroenterol 2006;101(suppl 2):S489.
44. Saad R, Chey WD. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation. Expert Rev Gastroenterol Hepatol 2008;2:497-508.
45. Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010;86:760-765.
46. Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22:312, e84.
47. Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic GMP. Gastroenterology 2013;145:1334- 1346, e1-e11.
48. Feng B, Kiyatkin ME, La JH, et al. Activation of guanylate cyclase- C attenuates stretch responses and sensitization of mouse colorectal afferents. J Neurosci 2013;33:9831-989.
49. Silos-Santiago I, Hannig G, Eutamene H, et al. Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/ guanylate cyclase-C/cGMP activation. Pain 2013;154:1820-1830.
50. McWilliams V, Whiteside G, McKeage K. Linaclotide: first global approval. Drugs 2012;72:2167-2175.
51. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527-536.
52. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-1724.
53. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702-1712.
54. Quigley EM, Tack J, Chey WD, et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013;37:49-61.
55. Chey WD, Lavins BJ, Shiff SJ, et al. Determining the minimum duration for initial treatment with linaclotide in IBS-C patients: results from pooled phase 3 trials. Gastroenterology 2013;144:S537-S538.
56. Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest 1971;50:1569-1577
57. Bajor A, Gillberg PG, Abrahamsson H. Bile acids: short and long term effects in the intestine. Scand J Gastroenterol 2010;45:645-664.
58. Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013;11:1270-1275, e1.
59. Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012;10:1009-1015, e3.
60. Mok HY, Bell GD, Dowling RH. Effect of different doses of chenodeoxycholic acid on bile-lipid composition and on frequency of side effects in patients with gallstones. Lancet 1974;2:253-257.
61. Fromm H, Sarva RP, Ravitch MM, McJunkin B, Farivar S, Amin P. Effects of jejunoileal bypass on the enterohepatic circulation of bile acids, bacterial flora in the upper small intestine, and absorption of vitamin B12. Metabolism 1983;32:1133-1141.
62. Bazzoli F, Malavolti M, Petronelli A, Barbara L, Roda E. Treatment of constipation with chenodeoxycholic acid. J Int Med Res 1983;11:120-123.
63. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010;8:159-165.
64. Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs 2013;22:277-284.
65. Shailubhai K. Therapeutic applications of guanylate cyclase-C receptor agonists. Curr Opin Drug Discov Devel 2002;5:261-268.
66. Bharucha AE, Waldman SA. Taking a lesson from microbial diarrheagenesis in the management of chronic constipation. Gastroenterology 2010;138:813-817.
67. Miner PB, Surowitz R, Fogel R, et al. Plecanatide, a novel guanylate- cyclase C (GC-C) receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation (CIC): results from a 951 patient, 12 week, multi-center trial. Digestive Diseases Week 2013, May 21, Orange County Convention Center, Orlando, FL: 925g.
68. Jadav AM, McMullin CM, Smith J, Chapple K, Brown SR. The association between prucalopride efficacy and constipation type. Tech Coloproctol 2013;17:555-559.
69. 4 receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002;16:603-612.
70. Camilleri M, Van Outryve MJ, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010;32: 1113-1123.
71. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35:745-767.
72. Cinca R, Chera D, Gruss HJ, Halphen M. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation - a comparison in a controlled environment. Aliment Pharmacol Ther 2013;37:876-886.
73. 4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome. Neurogastroenterol Motil 2011;23:754, e332.
74. Maneerattanaporn M, Chang L, Chey WD. Emerging pharmacological therapies for the irritable bowel syndrome. Gastroenterol Clin North Am 2011;40:223-243.
75. Mansour NM, Ghaith O, El-Halabi M, Sharara AI. A prospective randomized trial of mosapride vs. placebo in constipation-predominant irritable bowel syndrome. Am J Gastroenterol 2012;107:792- 793.
76. Spencer AG, Jacobs JW, Leadbetter MR, et al. RDX5791, a first-in-class minimally systemic NHE3 inhibitor in clinical development for CIC and IBS-C, increases intestinal sodium leading to enhanced intestinal fluid volume and transit. Gastroenterology 2011; 140(suppl 1):S99.
77. 3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther 2003;18:1039-1048.
78. Itoh T, Yamakawa J, Mai M, Yamaguchi N, Kanda T. The effect of the herbal medicine dai-kenchu-to on post-operative ileus. J Int Med Res 2002;30:428-432.
79. Takeda T, Kamiura S, Kimura T. Effectiveness of the herbal medicine daikenchuto for radiation-induced enteritis. J Altern Complement Med 2008;14:753-755.
80. Kawasaki N, Nakada K, Nakayoshi T, et al. Effect of Dai-kenchu-to on gastrointestinal motility based on differences in the site and timing of administration. Dig Dis Sci 2007;52:2684-2694.
81. Kawasaki N, Nakada K, Suzuki Y, Furukawa Y, Hanyu N, Kashiwagi H. Effect of Dai-kenchu-to on gastrointestinal motility and gastric emptying. Int J Surg 2009;7:218-222.
82. Borowiec AM, Fedorak RN. The role of probiotics in management of irritable bowel syndrome. Curr Gastroenterol Rep 2007;9:393- 400.
83. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009;104:1033-1049.
84. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-1590.
85. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551.
86. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-332.
87. Attaluri A, Donahoe R, Valestin J, Brown K, Rao SS. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Aliment Pharmacol Ther 2011;33:822-828.
88. Chang CC, Lin YT, Lu YT, Liu YS, Liu JF. Kiwifruit improves bowel function in patients with irritable bowel syndrome with constipation. Asia Pac J Clin Nutr 2010;19:451-457.